Passage Bio
PASG
44 hedge funds and large institutions have $21.6M invested in Passage Bio in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 9 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding
Funds holding: 44 → 44 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0.08% less ownership
Funds ownership: 3.13% → 3.05% (-0.08%)
20% less capital invested
Capital invested by funds: $27.1M → $21.6M (-$5.49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$541K |
| 2 |
Morgan Stanley
New York
|
+$520K |
| 3 |
SC
Shay Capital
New York
|
+$86.6K |
| 4 |
Jane Street
New York
|
+$42.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$32.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.57M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$282K |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$37.7K |
| 4 |
Two Sigma Investments
New York
|
-$31.7K |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$24.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$548 | -39 | Closed |
|
52
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$45 | -3 | Closed |
|
53
Simplex Trading
Chicago,
Illinois
| – | +$378 | +29 | New |
|
PASG Hedge Fund Activity: Q4 2024 in Review
44 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2024, worth a combined $21.6M — down 20% from $27.1M a quarter earlier.
Fund positioning in PASG was balanced in Q4 2024: 9 funds opened new positions, 9 closed out, 10 added to existing stakes and 9 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $541K. The largest seller was OrbiMed, cutting an estimated $1.57M.
- 44 institutional investors held Passage Bio (PASG) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $21.6M of Passage Bio stock for Q4 2024, down 20% quarter-over-quarter.
- 9 funds opened new Passage Bio positions in Q4 2024 and 9 closed out, a net change of 0 holders.
- The largest Passage Bio buyer in Q4 2024 was Lynx1 Capital Management, an estimated $541K added.
- The largest Passage Bio seller in Q4 2024 was OrbiMed, an estimated $1.57M sold.
Based on aggregated 13F filings for Q4 2024.